Impact of Liraglutide 3.0 on Body Fat Distribution
Status:
Completed
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo
in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk
for cardiovascular disease after 40 weeks on-treatment.